AbbVie's Humira no longer holds the top spot for pharmaceutical ad spending as the drugmaker shifts resources to newer therapies like rheumatoid arthritis drug Rinvoq and psoriasis drug Skyrizi. Regeneron and Sanofi spent an estimated $24 million on Dupixent ads last month, moving to the top of the TV ad spend chart.

The FDA sent revised emergency use authorization letters to Eli Lilly and Co. and Regeneron, ordering the companies to monitor new coronavirus variants and possibly perform additional studies on their authorized COVID-19 antibody drugs against the new variants. The letters focus on existing EUAs for Eli Lilly's bamlanivimab and its combination with etesevimab, and on Regeneron's antibody cocktail composed of casirivimab and imdevimab.

A positive opinion was adopted by the European Medicines Agency's Committee for Medicinal Products for Human Use for Regeneron's COVID-19 antibody cocktail REGEN-COV, or casirivimab plus imdevimab, as treatment for patients at high-risk for progressing to severe COVID-19 who do not require supplemental oxygen. An Independent Data Monitoring Committee said the treatment showed "clear efficacy" in the late-stage trial where vaccination with REGEN-COV prevented symptomatic COVID-19 infections 100%, and the IDMC recommended enrollment for the placebo group should be halted.